| abstract |
FIELD: pharmacology. n SUBSTANCE: ophthalmic composition for ocular hypertension treatment comprises at least one therapeutically active agent in a concentration of 0.01 to 0.12% (w/v), at least one tonicity agent, glycerin or mannitol, a solubilizer-polysorbate 80 and a preservative- benzalkonium chloride. The therapeutically active agent has the structure where X 1 and X 2 independently represent CH 2 , O or S, and R 1 is H or C 1 -C 6 alkyl. n EFFECT: application of a group of inventions allows to increase the efficiency of ocular hypertension treatment due to a novel combination of ingredients of the composition where the active agent solubility is increased. n 19 cl, 8 tbl, 10 ex |